Safety & Side Effects
Across its published reports, amycretin's side-effect profile is gastrointestinal, dose-related and mostly mild to…
Mostly the gut, with class questions to watch
Across its published reports, amycretin's side-effect profile is gastrointestinal, dose-related and mostly mild to moderate. In the oral first-in-human trial every one of the 364 events was mild or moderate; in the subcutaneous early-phase trial the majority were mild to moderate, which is a weaker statement and worth reading precisely. The 2026 phase 2 papers describe the same pattern.
This unit separates what was measured from what was only screened for, and is honest that the long-term safety record for amycretin does not exist yet. One rule runs through it: serious-adverse-event percentages here include placebo recipients in their denominators, so this unit gives counts.
Key terms
The gut side effects
The most common of amycretin's observed side effects were gastrointestinal; for the oral first-in-human trial the sponsor names them as mainly nausea and vomiting, plus decreased appetite. In the oral phase 1, all adverse events were mild or moderate and GI events made up about half. In the subcutaneous trial, gastrointestinal events were again the most common treatment-emergent adverse events and the majority were mild to moderate, a weaker statement than "all" and worth reading precisely. In the oral phase 2 cohort the dose relationship is visible directly: gastrointestinal events in 14 of 54 participants on 6 mg, 21 of 51 on 25 mg and 24 of 51 on 50 mg, against seven of 30 on placebo.
Read what that chart is: a dose-by-dose count of gastrointestinal events from one abstract, and it tracks dose, not time. The paper behind it adds the timing: its gastrointestinal events occurred mainly during the dose-escalation period, when doses were still rising.
The reassuring part is that the subcutaneous abstract reports the majority of events as mild to moderate and resolving by the end of the study. The unreassuring part is that they are dose-related: in the oral phase 2 cohort above they rose with dose, and the higher doses are where the biggest weight figures came from. The independent network analysis found gastrointestinal events generally more frequent than with placebo, particularly for oral amycretin.
AdvancedTwo gastric-slowing arms, and what the gut data show
Both GLP-1 and amylin slow gastric emptying, so amycretin carries two gastric-slowing arms. That is a reason to watch its gut side effects, not a measured cause of them: no source this course cites ties amycretin's nausea to either arm. What the sources show is the pattern. A review of amylin analogues describes gastrointestinal side effects, especially nausea, similar to those reported for GLP-1 drugs and common while the dose is started and raised. In the independent network meta-analysis, both oral amycretin dose strata carried a higher estimated risk of gastrointestinal events than semaglutide 2.4 mg. In the oral first-in-human trial every event was mild or moderate and in the subcutaneous trial the majority were, which is a weaker statement. Whether the higher-dose GI burden is tolerable for most people over the long term is an open question phase 3 must answer.